BioSpace News Archive

Curadev, a drug discovery and development company, announced today a significant milestone in its development of drugs targeting the immune system to treat cancer.

Roshal Health, a new leader providing hospital grade, on-site, and on-demand ultrasound and echocardiogram services to ERs, micro-hospitals, rural hospitals, and hospital offsite facilities, announced that it secured $10 million in financing.

Metabolica Health Inc. (“Metabolica” or the “Company”) a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation

February 27, 2024) - In a Pharma industry first from the floor of Pittcon this week, Phizzle will remotely operate both a Beckman Coulter and a Climet air particle counter at the same time via a single user interface.

Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company developing novel topical therapies for inflammatory skin diseases and skin cancer, is pleased to announce that it will soon begin a GLP toxicology study for DB-007-4, a potential best-in-class, first line topical treatment for inflammatory skin diseases such as acne, atopic dermatitis (AD), and rosacea.

PharmaEssentia USA Corporation announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have recently been updated to include ropeginterferon alfa-2b-njft, marketed as BESREMi®, as a preferred first-line cytoreductive therapy option for the treatment of adults with symptomatic, low-risk polycythemia vera.

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board.

February 27, 2024 – Proscia®, a leading provider of digital and computational pathology solutions, today announced that Pramana, Inc.,

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”) announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287, Gain’s lead drug candidate for the treatment of GBA1 Parkinson’s disease.